H.C. Wainwright analyst Emily Bodnar downgraded MiNK Therapeutics (INKT) to Neutral from Buy with a $35 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK Therapeutics announces publication of article on CAR-iNKT in Frontiers
- MiNK Therapeutics Enters $50M Sales Agreement with B. Riley
- Why Is MiNK Therapeutics Stock (INKT) Down 30% Today?
- MiNK Therapeutics Announces Clinical Trial Success
- William Blair downgrades MiNK on valuation after 700% rally